Porton Biopharma Digital Brochure - page 6

Porton Biopharma’s strategy as a new company with a
distinguished heritage is to grow our existing business, develop
our product pipeline and build relationships across the industry.
We were corporatised out of Public Health England on 1st April
2015, to enable us to grow the business of developing and
manufacturing life-saving products.
The company is built upon decades of biopharmaceutical
experience, including the successful licensure of many therapies
that now save thousands of lives every year and generate
revenues from world-wide sales. We have state-of-the-art cGMP
manufacturing facilities which are licensed by the MHRA and FDA
where we manufacture our own biopharmaceutical products.
With a multi-skilled workforce of approximately 300 and an ongoing
programme of investing in our facilities, we are focused on continual
improvement and the delivery of products that make
a real difference to patients’ lives.
At PBL we offer expertise in developmental production of biologicals,
including product characterisation, process and analytical validation,
and scalability for market. Allied with experience of regulatory
compliance gained from the licensure of our own products, this puts
us in an ideal position to offer expertise and enable our partners to
successfully bring their products to market.
Our mission is to protect peoples’ health through
the quality-assured development and production
of biopharmaceuticals.
1,2,3,4,5 7,8
Powered by FlippingBook